As part of our ongoing efforts to help keep medications affordable while maintaining quality care, we’re reaching out to select Medicare members currently prescribed Prolia® or Xgeva® to encourage discussions with their providers about transitioning to a covered biosimilar. Covered biosimilars include:
- Prolia biosimilars
- Jubbonti
- Bildyos
- Enoby
- Xgeva biosimilars
- Wyost
- Bilprevda
- Xtrenbo
Members may contact your office after receiving outreach regarding these treatment options. If a covered biosimilar is clinically appropriate, we encourage providers to consider transitioning eligible members to help reduce costs while maintaining the safety and effectiveness of treatment.
As always, treatment decisions should be based on clinical judgement and the individual needs of each member. Refer to our Medicare Part B Medical Drug List (MDL) and our Medicare Part D Approved Drug List (ADL) for coverage information.